Department of Radiation Oncology, BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada.
Cancer Surveillance and Outcomes, BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada.
Radiat Oncol. 2020 Jun 1;15(1):136. doi: 10.1186/s13014-020-01576-6.
To validate the Radiation Therapy Oncology Group (RTOG) and European Society for Radiotherapy and Oncology (ESTRO) breast cancer nodal clinical target volumes (CTVs) and to investigate the Radiotherapy Comparative Effectiveness Consortium (RADCOMP) Posterior Neck volume in relation to regional nodal recurrences (RNR).
From a population-based database, 69 patients were identified who developed RNR after curative treatment for breast cancer. RNRs were detected with 18-fluorodeoxyglucose-positron emission tomography-computed tomography (PET/CT). All patients were treatment-naïve for RNR when imaged. The RTOG and ESTRO nodal CTVs and RADCOMP Posterior Neck volumes were contoured onto a template patient's CT. RNRs were contoured on each PET/CT and deformed onto the template patient's CT. Each RNR was represented by a 5 mm diameter epicentre, and categorized as 'inside', 'marginal' or 'outside' the CTV boundaries.
Sixty-nine patients with 226 nodes (median 2, range 1-11) were eligible for inclusion. Thirty patients had received adjuvant tangent and regional nodal radiotherapy, 16 tangent-only radiotherapy and 23 no adjuvant radiotherapy. For the RTOG CTVs, the RNR epicentres were 70% (158/226) inside, 4% (8/226) marginal and 27% (60/226) outside. They included the full extent of the RNR epicentres in 38% (26/69) of patients. Addition of the RADCOMP Posterior Neck volume increased complete RNR coverage to 48% (33/69) of patients. For the ESTRO CTVs, the RNR epicentres were 73% (165/226) inside, 2% (4/226) marginal and 25% (57/226) outside. They included the full extent of the RNR epicentres in 57% (39/69) of patients. Addition of the RADCOMP Posterior Neck volume increased complete RNR coverage to 70% (48/69) of patients.
The RTOG and ESTRO breast cancer nodal CTVs do not fully cover all potential areas of RNR, but the ESTRO nodal CTVs provided full coverage of all RNR epicentres in 19% more patients than the RTOG nodal CTVs. With addition of the RADCOMP Posterior Neck volume to the ESTRO CTVs, 70% of patients had full coverage of all RNR epicentres.
为了验证放射治疗肿瘤学组(RTOG)和欧洲放射肿瘤学会(ESTRO)乳腺癌淋巴结临床靶区(CTV),并研究放射治疗比较效果研究联盟(RADCOMP)后颈区体积与区域淋巴结复发(RNR)的关系。
从一个基于人群的数据库中,确定了 69 例接受根治性治疗后发生乳腺癌 RNR 的患者。RNR 通过 18-氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(PET/CT)检测。所有患者在进行图像检查时均未接受 RNR 的放射治疗。将 RTOG 和 ESTRO 淋巴结 CTV 和 RADCOMP 后颈区体积描绘到模板患者的 CT 上。将 RNR 描绘在每个 PET/CT 上,并变形到模板患者的 CT 上。每个 RNR 用一个 5mm 直径的中心点表示,并分类为“内部”、“边缘”或“外部”CTV 边界。
69 例患者共 226 个淋巴结(中位数 2 个,范围 1-11 个)符合纳入标准。30 例患者接受了辅助切线和区域淋巴结放疗,16 例仅接受了切线放疗,23 例未接受辅助放疗。对于 RTOG CTV,RNR 中心点 70%(158/226)位于内部,4%(8/226)位于边缘,27%(60/226)位于外部。它们在 38%(26/69)的患者中完全覆盖了 RNR 中心点。加入 RADCOMP 后颈区体积后,完全覆盖 RNR 的比例增加到 48%(33/69)。对于 ESTRO CTV,RNR 中心点 73%(165/226)位于内部,2%(4/226)位于边缘,25%(57/226)位于外部。它们在 57%(39/69)的患者中完全覆盖了 RNR 中心点。加入 RADCOMP 后颈区体积后,完全覆盖 RNR 的比例增加到 70%(48/69)。
RTOG 和 ESTRO 乳腺癌淋巴结 CTV 不能完全覆盖所有潜在的 RNR 区域,但 ESTRO 淋巴结 CTV 在 19%的患者中完全覆盖了所有 RNR 中心点,比 RTOG 淋巴结 CTV 多。加入 RADCOMP 后颈区体积后,ESTRO CTV 中 70%的患者完全覆盖了所有 RNR 中心点。